首页 > 市场调查报告书 > 医疗设备

药物递输设备 DDS

北美透皮给药系统市场预测至 2030 年 - 区域分析 - 按类型、应用和配销通路

市场调查报告书

商品编码

1510744

北美透皮给药系统市场预测至 2030 年 - 区域分析 - 按类型、应用和配销通路

North America Transdermal Drug Delivery System Market Forecast to 2030 - Regional Analysis - by Type, Application, and Distribution Channel

出版日期: 2024年05月07日 | 出版商:

The Insight Partners | 英文 109 Pages | 订单完成后即时交付

价格

简介目录图表

北美透皮给药系统市场预计将从2022年的149.7762亿美元成长到2030年的209.5837亿美元。

慢性病盛行率的增加推动北美透皮给药系统市场

心绞痛、动脉粥状硬化、心绞痛和急性心肌梗塞等心血管疾病（CVD）是世界上常见的死因之一。据世界卫生组织称，CVD 是全球每年约 1,790 万人死亡的主要原因。许多药物可用于治疗心血管疾病，但传统的胶囊和片剂无法有效控制疾病。这强调了对新型药物递送系统的需求，该系统可提供延长的药物生物利用度和标靶药物递送至心血管系统受影响的区域。与常规口服药物相比，经皮给药系统在治疗心血管疾病方面具有许多优势。将含有药物颗粒的透皮贴片涂抹在皮肤表面。心臟补片为改善细胞植入提供了一个绝佳的平台。例如，最近开发的血管化心臟补片显示出治疗缺血性心臟损伤的巨大潜力。硝酸甘油透皮贴片用于预防冠状动脉疾病患者的心绞痛（胸痛）发作。它们的作用是放鬆血管并减轻心臟压力，从而降低对氧气的需求。然而，这些贴片不能用于治疗已经开始的心绞痛发作。

根据阿兹海默症协会的报告，2019年，阿兹海默症在美国主要死因中排名第六，2020年和2021年则排名第七。根据美国国立卫生研究院 2023 年的统计数据，约 670 万 65 岁及以上的美国人（即每 9 人中就有 1 人，即人口的 10.8%）患有阿兹海默症。患有阿兹海默症的人的比例随着年龄的增长而增加。 65-74岁的人中有5%、75-84岁的人有13.1%、85岁及以上的人有33.3%患有阿兹海默症。根据2021 年发布的《全球年轻发病痴呆症盛行率》报告，美国30-64 岁的年轻发病痴呆症盛行率估计为每10 万人中就有110 人，即总共约20 万名美国人。卡巴拉汀贴片用于治疗与轻度、中度或重度阿兹海默症相关的痴呆症（记忆丧失）或与帕金森氏症相关的轻至中度痴呆。卡巴拉汀和多奈哌齐是胆碱酯酶抑制剂，表现出剂量反应关係，药物剂量越高，疗效越好。它是一种小的亲脂性和亲水性分子，化学性质非常适合透皮递送。

糖尿病是一种危及生命的慢性疾病，没有专门的治疗方法。这两种类型的糖尿病都会导致身体不同部位出现各种问题，并增加过早死亡的整体风险。根据国际糖尿病联盟（IDF）糖尿病图谱第10版报告，2021年，全球有5.37亿成年人（20-79岁）患有糖尿病，到2030年这一数字可能达到6.43亿，到2045年将达到7.83亿。然而，最近人们关注的是一种智慧贴片，它可以在需要时提供胰岛素，简化胰岛素摄取并激活有针对性的作用。

因此，心血管疾病、阿兹海默症和糖尿病等慢性疾病发生率的增加促进了透皮给药系统市场的成长。

北美透皮给药系统市场概况

北美透皮给药系统市场分为美国、加拿大和墨西哥。 2022年，美国占据北美透皮给药系统市场最大份额。透皮给药系统的不断创新和中枢神经系统疾病的增加是预计在预测期内加速北美透皮给药系统市场成长的少数因素之一。此外，不断增加的研发活动和新产品的推出正在推动透皮给药系统市场的发展。根据美国心臟协会 (AHA) 的数据，心血管疾病 (CVD) 仍然是美国的首要死因。据 CDC 称，2021 年，CVD 导緻美国约 695,000 人死亡，约占美国五分之一的死亡人数。心血管疾病、糖尿病、慢性疼痛和其他慢性疾病的盛行率不断上升，推动了对有效、便利的治疗方案的需求。医疗贴片提供了一种非侵入性且患者友善的方法来提供药物并管理与这些慢性病相关的症状。 TDDS 的不断进步，例如穿戴式感测器和柔性电子产品，有助于透皮给药系统市场的成长。这些进步可以实现更准确的剂量、增强的患者监测并提高患者的依从性。根据Biomaterials Research 2021年发表的题为《透皮给药系统的最新进展》的报告，微针在TDDS模式中引起了极大关注，它通过结合微针的优点克服了现有简单涂抹型和贴片型针的限制。这些TDDS的进展可以为控制心血管和中枢神经系统疾病、糖尿病、神经肌肉疾病以及传染病和局部传染病的流行提供动力。

个人化药物的日益增长的趋势，即针对个别患者量身定制治疗方案，促进了提供受控和有针对性的药物输送的医疗贴剂的开发。这种客製化可以改善患者的治疗效果并提高治疗效果。例如，2020年，Reddy's Laboratories在美国市场推出了授权通用版NitroDur（硝酸甘油）透皮输注系统。随着人们对家庭医疗保健和远端患者监测的日益重视，医疗贴片为在传统医疗保健环境之外输送药物和监测生命体征提供了便捷的解决方案。美国透皮给药系统市场受到慢性病盛行率上升、技术进步以及对个人化药物日益关注等因素的影响。

北美透皮给药系统市场收入及 2030 年预测（百万美元）

北美透皮给药系统市场细分

北美透皮给药系统市场按类型、应用、配销通路和国家细分。

根据类型，北美透皮给药系统市场分为透皮贴片、透皮凝胶、透皮喷雾等。到2022年，透皮凝胶细分市场占据北美透皮给药系统市场的最大份额。。

在应用方面，北美透皮给药系统市场细分为心血管疾病、中枢神经系统疾病、疼痛管理、荷尔蒙应用和其他应用。到2022年，疼痛管理领域占据北美透皮给药系统市场的最大份额。荷尔蒙应用进一步细分为透皮雌激素和黄体素治疗以及睪固酮替代疗法。

根据配销通路，北美透皮给药系统市场分为医院药房、零售药房、线上药房等。 2022年，医院药局部门在北美透皮给药系统市场中占据最大份额。

依国家划分，北美透皮给药系统市场分为美国、加拿大和墨西哥。 2022年，美国主导北美透皮给药系统市场。

Boehringer Ingelheim International GmbH、GSK Plc、Hisamitsu Pharmaceutical Co Inc、Johnson & Johnson、Lavipharm SA、Luye Pharma Group Ltd、Novartis AG、Purdue Pharma LP、UCB SA 和 Viatris Inc 是北美透皮用药领域的一些领先公司药物传输系统市场。

Cardiovascular diseases (CVDs) such as angina, atherosclerosis, pectoris, and acute myocardial infarction are among the common causes of mortality in the world. According to the WHO, CVDs are the major cause of ~17.9 million deaths worldwide every year. Many medicines are commercially available for the treatment of CVDs but conventional capsules and tablets are unable to effectively control the ailment. This underlines the need for novel drug delivery systems providing prolonged drug bioavailability and targeted drug delivery to the affected areas of the cardiovascular system. Transdermal drug delivery systems offer many advantages over regular orally administered drugs to treat cardiovascular diseases. Transdermal patches, encompassing drug particles, are applied on the skin surface. A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. They work by relaxing the blood vessels and reducing the stress on the heart, thereby lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.

According to the Alzheimer's association report, in 2019, Alzheimer disease was ranked sixth and in 2020 and 2021 it was ranked seventh among the leading causes of death in in the US. According to the 2023 stats by the National Institute of Health, ~6.7 million Americans (i.e., 1 in 9 people or 10.8% of the population), aged 65 and older, have Alzheimer's dementia. The percentage of people with Alzheimer's dementia increases with age. 5% of people aged 65-74, 13.1% aged 75-84, and 33.3% aged 85 and above have Alzheimer's dementia. According to the "Global Prevalence of Young-Onset Dementia" report published in 2021, the prevalence of younger-onset dementia in the US is estimated at 110 of every 100,000 people aged 30-64 years, or ~200,000 Americans in total. Rivastigmine patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer's disease or mild-to-moderate dementia associated with Parkinson's disease. Rivastigmine and donepezil are cholinesterase inhibitors exhibiting a dose-response relationship, with higher doses of the drugs demonstrating greater efficacy. It is a small, lipophilic, and hydrophilic molecule that is chemically well-suited for transdermal delivery.

Diabetes is a life-threatening chronic disease having no specialized cure. Both types of diabetes can lead to various problems in different body parts and increase the overall risk of premature death. According to the International Diabetes Federation (IDF) Diabetes Atlas 10th edition reports, in 2021, globally 537 million adults (20-79 years) were diabetic, and the number is likely to reach 643 million by 2030 and 783 million by 2045. Exogenous insulin is usually administered subcutaneously for diabetes management. However, the recent attention toward a smart patch that delivers insulin when needed, simplifying insulin intake and activating targeted action.

Thus, the increasing incidences of chronic diseases such as cardiovascular diseases, Alzheimer's disease, and diabetes bolster the growth of the transdermal drug delivery system market.

North America Transdermal Drug Delivery System Market Overview

The North American transdermal drug delivery system market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America transdermal drug delivery system market. The growing innovations in the transdermal drug delivery systems and increasing central nervous system disorders are among the few factors projected to accelerate the growth of the North America transdermal drug delivery system market during the forecast period. Moreover, increasing R&D activities and the introduction of novel products are propelling the market for transdermal drug delivery systems. According to the American Heart Association (AHA), cardiovascular disease (CVD) remains the leading cause of death in the US. According to the CDC, in 2021, CVD accounted for ~695,000 deaths and ~1 in 5 deaths in the US. The rising prevalence of cardiovascular disease, diabetes, chronic pain conditions, and other chronic diseases drives the demand for effective and convenient treatment options. Medical patches offer a noninvasive and patient-friendly approach to deliver medication and manage symptoms associated with these chronic conditions. Ongoing advancements in TDDS, such as wearable sensors and flexible electronics, contribute to the growth of the transdermal drug delivery system market. These advancements allow for more accurate dosing, enhanced patient monitoring, and improved patient compliance. According to a report titled "Recent advances in transdermal drug delivery systems," published by Biomaterials Research in 2021, microneedles attract significant attention among TDDS modalities, which overcome the limitations of the existing simple application type and patch-type needles by combining the advantages of microneedles to obtain higher treatment efficiency and effects. Advances in these TDDS can provide the driving force for controlling the prevalence of cardiovascular and central nervous system diseases, diabetes, neuromuscular diseases, and infectious and localized infectious diseases.

The growing trend of personalized medicines, where treatments are tailored to individual patients, has boosted the development of medical patches that offer controlled and targeted drug delivery. This customization allows for better patient outcomes and improved therapeutic efficacy. For instance, in 2020, Reddy's Laboratories launched an Authorized Generic Version of NitroDur (nitroglycerin) Transdermal Infusion System in the US market. With the growing emphasis on home healthcare and remote patient monitoring, medical patches offer a convenient solution for delivering medications and monitoring vital signs outside traditional healthcare settings. The US transdermal drug delivery system market is influenced by factors such as the increasing prevalence of chronic diseases, rising technological advancements, and growing focus on personalized medicines.

North America Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)

North America Transdermal Drug Delivery System Market Segmentation

The North America transdermal drug delivery system market is segmented into type, application, distribution channel, and country.

Based on type, the North America transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the North America transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the North America transdermal drug delivery system market is segmented into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the North America transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

Based on distribution channel, the North America transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the North America transdermal drug delivery system market in 2022.

Based on country, the North America transdermal drug delivery system market is segmented into the US, Canada, and Mexico. The US dominated the North America transdermal drug delivery system market in 2022.

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, Purdue Pharma LP, UCB SA, and Viatris Inc are some of the leading companies operating in the North America transdermal drug delivery system market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Transdermal Drug Delivery System Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Chronic Diseases
- 4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
- 4.1.3 High Demand for Self-Administration of Drugs
4.2 Market Restraints
- 4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
4.3 Market Opportunities
- 4.3.1 Advancements in Smart Patches and 3D-Printed Patches
4.4 Future Trends
- 4.4.1 Strategic Initiatives by Manufacturers
4.5 Impact Analysis

5. Transdermal Drug Delivery System Market - North America Market Analysis

5.1 North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 - 2030

6. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Type

6.1 Overview
6.2 North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Transdermal Patches
- 6.3.1 Overview
- 6.3.2 Transdermal Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 Drug-in-Adhesive Patches
    - 6.3.2.1.1 Overview
    - 6.3.2.1.2 Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.2 Matrix Patches
    - 6.3.2.2.1 Overview
    - 6.3.2.2.2 Matrix Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.3 Reservoir Membrane Patches
    - 6.3.2.3.1 Overview
    - 6.3.2.3.2 Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.4 Vapor Patches
    - 6.3.2.4.1 Overview
    - 6.3.2.4.2 Vapor Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Transdermal Gels
- 6.4.1 Overview
- 6.4.2 Transdermal Gels: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Transdermal Sprays
- 6.5.1 Overview
- 6.5.2 Transdermal Sprays: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Application

7.1 Overview
7.2 North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cardiovascular Diseases
- 7.3.1 Overview
- 7.3.2 Cardiovascular Diseases: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Central Nervous System Disorders
- 7.4.1 Overview
- 7.4.2 Central Nervous System Disorders: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Pain Management
- 7.5.1 Overview
- 7.5.2 Pain Management: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.5.2.1 Opioid
    - 7.5.2.1.1 Overview
    - 7.5.2.1.2 Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.5.2.2 Non-Opioid
    - 7.5.2.2.1 Overview
    - 7.5.2.2.2 Non-Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Hormonal Applications
- 7.6.1 Overview
- 7.6.2 Hormonal Applications: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.6.2.1 Transdermal Estrogen & Progesterone Therapy
    - 7.6.2.1.1 Overview
    - 7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.6.2.2 Testosterone Replacement
    - 7.6.2.2.1 Overview
    - 7.6.2.2.2 Testosterone Replacement: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Other Application
- 7.7.1 Overview
- 7.7.2 Other Application: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - Country Analysis

9.1 North America Transdermal Drug Delivery System Market
- 9.1.1 North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
  - 9.1.1.1 US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Overview
    - 9.1.1.1.2 US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.3 US: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.1.3.1 US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.1.4 US: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.4.1 US: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.4.2 US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.5 US: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.2 Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Overview
    - 9.1.1.2.2 Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.3 Canada: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.2.3.1 Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.2.4 Canada: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.4.1 Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.4.2 Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.5 Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.3 Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 Overview
    - 9.1.1.3.2 Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.3 Mexico: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.3.3.1 Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.3.4 Mexico: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.4.1 Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.4.2 Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.5 Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Transdermal Drug Delivery System Market Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Transdermal Drug Delivery System Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Johnson & Johnson
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 GSK Plc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Viatris Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Boehringer Ingelheim International GmbH
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Luye Pharma Group Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Lavipharm SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Purdue Pharma LP
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 UCB SA
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. North America Transdermal Drug Delivery System Market Segmentation
Table 2. US: North America Transdermal Drug Delivery System Market, by Type - Revenue and Forecast to 2030 (US$ Million)
Table 3. US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type - Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America Transdermal Drug Delivery System Market, by Application - Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America Transdermal Drug Delivery System Market, For Pain Management by Application - Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application - Revenue and Forecast to 2030 (US$ Million)
Table 7. US: North America Transdermal Drug Delivery System Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada: North America Transdermal Drug Delivery System Market, by Type - Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type - Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America Transdermal Drug Delivery System Market, by Application - Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application - Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application - Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America Transdermal Drug Delivery System Market, by Type - Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type - Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico: North America Transdermal Drug Delivery System Market, by Application - Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application - Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application - Revenue and Forecast to 2030 (US$ Million)
Table 19. Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 20. Recent Inorganic Growth Strategies in the Transdermal Drug Delivery System Market
Table 21. Recent Organic Growth Strategies in the Transdermal Drug Delivery System Market
Table 22. Glossary of Terms, North America Transdermal Drug Delivery System Market

List Of Figures

Figure 1. North America Transdermal Drug Delivery System Market Segmentation, By Country
Figure 2. North America Transdermal Drug Delivery System Market: Key Industry Dynamics
Figure 3. North America Transdermal Drug Delivery System Market: Impact Analysis of Drivers and Restraints
Figure 4. North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2020 - 2030
Figure 5. North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Transdermal Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Matrix Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Vapor Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Transdermal Gels: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Transdermal Sprays: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
Figure 15. Cardiovascular Diseases: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Central Nervous System Disorders: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Pain Management: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Non-Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Hormonal Applications: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Testosterone Replacement: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Other Application: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 25. Hospital Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. Retail Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. Online Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. North America Transdermal Drug Delivery System Market, by Key Country - Revenue (2022) (US$ Million)
Figure 30. North America: North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
Figure 31. US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 32. Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 33. Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 34. Growth Strategies in the Transdermal Drug Delivery System Market